BiotechTube

PA21

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis Patients With Hyperphosphatemia

Conditions

Hemodialysis Patients With Hyperphosphatemia

Trial Timeline

Mar 18, 2013 → Aug 4, 2014

NCT ID
NCT01833494

About PA21

PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis Patients With Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01833494. Target conditions include Hemodialysis Patients With Hyperphosphatemia.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis Patients With Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (13)
🔄R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
🔄roxadustatAstellas PharmaPhase 3
✅DoravirineMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01852682Phase 3Completed
NCT01850641Phase 3Completed
NCT01833494Phase 3Completed

Competing Products

20 competing products in Hemodialysis Patients With Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP7991Astellas PharmaPhase 1
29
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP1585Astellas PharmaPhase 2
35
Kiklin capsulesAstellas PharmaPre-clinical
26
DoravirineMerckApproved
43
BPS804 + PlaceboNovartisPhase 2
27
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
40
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
[¹⁴C]EtelcalcetideAmgenPhase 1
29
Epoetin HospiraPfizerPhase 3
40
Epoetin HospiraPfizerPhase 3
40
sodium thiosulfateSanofiPre-clinical
26
EnoxaparineSanofiApproved
43
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
36